VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy
about
Development of New Molecular EZH2 on Lung Cancer Invasion and MetastasisRobust meta-analysis of gene expression using the elastic net.Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis.PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled RamucirumabModulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene MutationsThe microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinomaMutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.Effects of long noncoding RNA SPRY4-IT1-mediated EZH2 on the invasion and migration of lung adenocarcinoma.Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysisCombined analysis identifies six genes correlated with augmented malignancy from non-small cell to small cell lung cancer.MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells.The Prognostic Significance of Histone Lysine Demethylase JMJD3/KDM6B in Colorectal Cancer.
P2860
Q28072419-1CAEE9D6-21BB-4B09-9BD2-90DC68C45621Q35842461-713F5FBF-4B43-4277-8FCF-AE0F6E5FA9FAQ36453727-A132CBF3-B501-4B72-8814-35457ABCE17FQ36535436-6D39A1A7-E4E8-467A-8370-39536E3EA908Q36535735-9956FBF0-868E-4CD4-86DB-FFE70C56C90CQ37644821-5A0D8025-5A38-4984-A2D6-69B02B5123E1Q38594002-4796585D-2FD7-4363-907C-211064A11A84Q38695240-66F0D344-B6A0-4FD0-A6FD-84AA1282E175Q39281286-47B520BF-2B59-4DB1-B554-94506804BFD1Q41389873-371C9013-9A63-40B4-8778-EA98BB0FF932Q47114407-E20E2B66-3B4A-4F73-87F8-1A08E8E07C94Q51502591-C889C0EC-BC10-4B51-8CD3-946C02FA7AD4Q52913525-2902392B-2DD6-4A10-85DB-C629E03F90E5
P2860
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
VEGF/VEGFR-2 upregulates EZH2 ...... d and VEGFR-2-targeted therapy
@ast
VEGF/VEGFR-2 upregulates EZH2 ...... d and VEGFR-2-targeted therapy
@en
VEGF/VEGFR-2 upregulates EZH2 ...... d and VEGFR-2-targeted therapy
@nl
type
label
VEGF/VEGFR-2 upregulates EZH2 ...... d and VEGFR-2-targeted therapy
@ast
VEGF/VEGFR-2 upregulates EZH2 ...... d and VEGFR-2-targeted therapy
@en
VEGF/VEGFR-2 upregulates EZH2 ...... d and VEGFR-2-targeted therapy
@nl
prefLabel
VEGF/VEGFR-2 upregulates EZH2 ...... d and VEGFR-2-targeted therapy
@ast
VEGF/VEGFR-2 upregulates EZH2 ...... d and VEGFR-2-targeted therapy
@en
VEGF/VEGFR-2 upregulates EZH2 ...... d and VEGFR-2-targeted therapy
@nl
P2093
P2860
P1476
VEGF/VEGFR-2 upregulates EZH2 ...... d and VEGFR-2-targeted therapy
@en
P2093
Carmen Behrens
Erick Riquelme
George Simon
Heather Y Lin
J Jack Lee
John D Minna
Kevin R Coombes
Luc Girard
Milind Suraokar
P2860
P304
P356
10.1158/1078-0432.CCR-13-1916
P407
P577
2014-05-21T00:00:00Z